-
1
-
-
0032986775
-
The Australian National Medicinal Drug Policy
-
10.1046/j.1440-1762.1999.00291.x
-
Sansom L The Australian National Medicinal Drug Policy J Quality Clinical Practice 1999, 19:31-35. 10.1046/j.1440-1762.1999.00291.x
-
(1999)
J Quality Clinical Practice
, vol.19
, pp. 31-35
-
-
Sansom, L.1
-
3
-
-
84861112051
-
Justice
-
New York, Oxford University Press Beauchamp TL and Childress JF 5th
-
Beauchamp TL Childress JF Justice Principles of Biomedical Ethics New York, Oxford University Press Beauchamp TL and Childress JF 5th 2001, 225-282
-
(2001)
Principles of Biomedical Ethics
, pp. 225-282
-
-
Beauchamp, T.L.1
Childress, J.F.2
-
6
-
-
16544384964
-
The subsidy of pharmaceuticals in Australia: Processes and challenges
-
15527399
-
Sansom L The subsidy of pharmaceuticals in Australia: Processes and challenges Aust Health Rev 2004, 28:194-205. 15527399
-
(2004)
Aust Health Rev
, vol.28
, pp. 194-205
-
-
Sansom, L.1
-
8
-
-
0038408597
-
Evidence-based medicine as an instrument for rational health policy
-
10.1023/A:1022947707243 12769414
-
Biller-Andorno N Lie RK ter Meulen R Evidence-based medicine as an instrument for rational health policy Health Care Anal 2002, 10:261-275. 10.1023/A:1022947707243 12769414
-
(2002)
Health Care Anal
, vol.10
, pp. 261-275
-
-
Biller-Andorno, N.1
Lie, R.K.2
ter Meulen, R.3
-
9
-
-
0032507379
-
Ethics and evidence based medicine
-
Kerridge I Lowe M Henry D Ethics and evidence based medicine BMJ 1998, 316:151-153.
-
(1998)
BMJ
, vol.316
, pp. 151-153
-
-
Kerridge, I.1
Lowe, M.2
Henry, D.3
-
10
-
-
2342418618
-
Evidence based medicine guidelines: A solution to rationing or politics disguised as science?
-
1733818 15082812 10.1136/jme.2003.003145
-
Saarni SI Gylling HA Evidence based medicine guidelines: A solution to rationing or politics disguised as science? J Med Ethics 2004, 30:171-175. 1733818 15082812 10.1136/jme.2003.003145
-
(2004)
J Med Ethics
, vol.30
, pp. 171-175
-
-
Saarni, S.I.1
Gylling, H.A.2
-
11
-
-
0029384042
-
Evidence based medicine and ethics
-
1376770 8558537
-
Hope T Evidence based medicine and ethics J Med Ethics 1995, 21:259-260. 1376770 8558537
-
(1995)
J Med Ethics
, vol.21
, pp. 259-260
-
-
Hope, T.1
-
12
-
-
0029165307
-
Health Policy Approaches to Measuring and Valuing Human Life: Conceptual and Ethical Issues
-
1615602 7573617
-
Morrow RH Bryant JH Health Policy Approaches to Measuring and Valuing Human Life: Conceptual and Ethical Issues Am J Public Health 1995, 85:1356-1360. 1615602 7573617
-
(1995)
Am J Public Health
, vol.85
, pp. 1356-1360
-
-
Morrow, R.H.1
Bryant, J.H.2
-
13
-
-
2342441070
-
Ethical issues of cost effectiveness analysis and guideline setting in mental health care
-
1733826 15082807 10.1136/jme.2003.007047
-
Berghmans R Berg M van den Burg M ter Meulen R Ethical issues of cost effectiveness analysis and guideline setting in mental health care J Med Ethics 2004, 30:146-150. 1733826 15082807 10.1136/jme.2003.007047
-
(2004)
J Med Ethics
, vol.30
, pp. 146-150
-
-
Berghmans, R.1
Berg, M.2
van den Burg, M.3
ter Meulen, R.4
-
14
-
-
21644443971
-
Tailoring access to high cost, genetically targeted drugs
-
15963014
-
Hall WD Ward R Liauw WS Brien JE Lu CY Tailoring access to high cost, genetically targeted drugs Med J Aust 2005, 182:607-608. 15963014
-
(2005)
Med J Aust
, vol.182
, pp. 607-608
-
-
Hall, W.D.1
Ward, R.2
Liauw, W.S.3
Brien, J.E.4
Lu, C.Y.5
-
17
-
-
85082978480
-
Subsidised access to TNFa inhibitors: Is the rationale for exclusion of rheumatoid factor negative patients defensible? [comment]
-
[comment] 15487967
-
Sansom L Subsidised access to TNFa inhibitors: Is the rationale for exclusion of rheumatoid factor negative patients defensible? [comment] Med J Aust 2004, 181:457-458. 15487967
-
(2004)
Med J Aust
, vol.181
, pp. 457-458
-
-
Sansom, L.1
-
18
-
-
44949189440
-
Lack of evidence for an association between rheumatoid factor status and clinical response in patients with rheumatoid arthritis treated with tumour necrosis factor inhibitors
-
Lu CY Williams KM March LM Bertouch J Day RO Lack of evidence for an association between rheumatoid factor status and clinical response in patients with rheumatoid arthritis treated with tumour necrosis factor inhibitors Intern Med J 2004, 34:A104.
-
(2004)
Intern Med J
, vol.34
-
-
Lu, C.Y.1
Williams, K.M.2
March, L.M.3
Bertouch, J.4
Day, R.O.5
-
19
-
-
7044247960
-
Subsidised access to TNFa inhibitors: Is the rationale for exclusion of rheumatoid factor negative patients defensible?
-
15487967
-
Lu CY Williams KM March LM Bertouch J Day RO Subsidised access to TNFa inhibitors: Is the rationale for exclusion of rheumatoid factor negative patients defensible? Med J Aust 2004, 181:457. 15487967
-
(2004)
Med J Aust
, vol.181
, pp. 457
-
-
Lu, C.Y.1
Williams, K.M.2
March, L.M.3
Bertouch, J.4
Day, R.O.5
-
20
-
-
11844262650
-
Subsidised access to TNF-alpha inhibitors: Is the rationale for exclusion of rheumatoid factor negative patients defensible?
-
15651955
-
Mann EL Subsidised access to TNF-alpha inhibitors: Is the rationale for exclusion of rheumatoid factor negative patients defensible? Med J Aust 2005, 182:47-48. 15651955
-
(2005)
Med J Aust
, vol.182
, pp. 47-48
-
-
Mann, E.L.1
-
21
-
-
44949195753
-
-
Australian Government Department of Health and Ageing (cited 29 Dec 2007)
-
Australian Government Department of Health and Ageing Recommendations made by the Pharmaceutical Benefits Advisory Committee in March 2005. http://www.health.gov.au/internet/wcms/publishing.nsf/Content/ pbacrec-pbacrecmar05-copy2 (cited 29 Dec 2007)
-
Recommendations Made By the Pharmaceutical Benefits Advisory Committee in March 2005
-
-
-
22
-
-
0034715904
-
Accountability for reasonableness
-
1119050 11090498 10.1136/bmj.321.7272.1300
-
Daniels N Accountability for reasonableness BMJ 2000, 321:1300-1301. 1119050 11090498 10.1136/bmj.321.7272.1300
-
(2000)
BMJ
, vol.321
, pp. 1300-1301
-
-
Daniels, N.1
-
23
-
-
4344629209
-
Access to high cost drugs in Australia: Risk sharing scheme may set a new paradigm
-
514195 15321884 10.1136/bmj.329.7463.415
-
Lu CY Williams KM Day RO March LM Sansom L Bertouch J Access to high cost drugs in Australia: Risk sharing scheme may set a new paradigm BMJ 2004, 329:415-416. 514195 15321884 10.1136/bmj.329.7463.415
-
(2004)
BMJ
, vol.329
, pp. 415-416
-
-
Lu, C.Y.1
Williams, K.M.2
Day, R.O.3
March, L.M.4
Sansom, L.5
Bertouch, J.6
-
24
-
-
33845201146
-
Recent developments in targeting access to high cost medicines in Australia
-
10.1186/1743-8462-2-28
-
Lu CY Ritchie J Williams KM Day RO Recent developments in targeting access to high cost medicines in Australia Aus NZ Health Policy 2005, 2:28. 10.1186/1743-8462-2-28
-
(2005)
Aus NZ Health Policy
, vol.2
, pp. 28
-
-
Lu, C.Y.1
Ritchie, J.2
Williams, K.M.3
Day, R.O.4
-
25
-
-
39049114515
-
The views of stakeholders on controlled access schemes for high-cost antirheumatic biological medicines in Australia
-
10.1186/1743-8462-4-26
-
Lu CY Ritchie J Williams K Day R The views of stakeholders on controlled access schemes for high-cost antirheumatic biological medicines in Australia Aus NZ Health Policy 2007, 4:26. 10.1186/1743-8462-4-26
-
(2007)
Aus NZ Health Policy
, vol.4
, pp. 26
-
-
Lu, C.Y.1
Ritchie, J.2
Williams, K.3
Day, R.4
-
26
-
-
33644621310
-
Toward ethical review of health system transformations
-
1592698 16449582 10.2105/AJPH.2005.065706
-
Daniels N Toward ethical review of health system transformations Am J Public Health 2006, 96:447-451. 1592698 16449582 10.2105/AJPH.2005.065706
-
(2006)
Am J Public Health
, vol.96
, pp. 447-451
-
-
Daniels, N.1
-
27
-
-
33644833351
-
Access to tumour necrosis factor inhibitors for rheumatoid arthritis treatment under the Australian Pharmaceutical Benefits Scheme: Are we on target?
-
10.1111/j.1445-5994.2005.00992.x 16409309
-
Lu CY Williams KM Day RO Access to tumour necrosis factor inhibitors for rheumatoid arthritis treatment under the Australian Pharmaceutical Benefits Scheme: Are we on target? Intern Med J 2006, 36:19-27. 10.1111/ j.1445-5994.2005.00992.x 16409309
-
(2006)
Intern Med J
, vol.36
, pp. 19-27
-
-
Lu, C.Y.1
Williams, K.M.2
Day, R.O.3
-
28
-
-
38549133605
-
The funding and use of high-cost medicines in Australia: The example of anti-rheumatic biological medicines
-
10.1186/1743-8462-4-2
-
Lu CY Williams K Day R The funding and use of high-cost medicines in Australia: The example of anti-rheumatic biological medicines Aus NZ Health Policy 2007, 4:2. 10.1186/1743-8462-4-2
-
(2007)
Aus NZ Health Policy
, vol.4
, pp. 2
-
-
Lu, C.Y.1
Williams, K.2
Day, R.3
-
29
-
-
0035459678
-
The ethics of pharmaceutical benefit management
-
10.1377/hlthaff.20.5.150 11558699
-
Burton SL Randel L Titlow K Emanuel EJ The ethics of pharmaceutical benefit management Health Aff (Millwood) 2001, 20:150-163. 10.1377/ hlthaff.20.5.150 11558699
-
(2001)
Health Aff (Millwood)
, vol.20
, pp. 150-163
-
-
Burton, S.L.1
Randel, L.2
Titlow, K.3
Emanuel, E.J.4
-
30
-
-
33646244039
-
Accessing health outcome data on high cost medicines in Australia
-
16618242
-
Lu CY Williams KM Day RO Accessing health outcome data on high cost medicines in Australia Med J Aust 2006, 184:411-413. 16618242
-
(2006)
Med J Aust
, vol.184
, pp. 411-413
-
-
Lu, C.Y.1
Williams, K.M.2
Day, R.O.3
|